Market Cap 5.25B
Revenue (ttm) 4.05B
Net Income (ttm) 22.20M
EPS (ttm) N/A
PE Ratio 10.28
Forward PE 11.38
Profit Margin 0.55%
Debt to Equity Ratio 0.65
Volume 2,077,800
Avg Vol 1,801,552
Day's Range N/A - N/A
Shares Out 49.12M
Stochastic %K 38%
Beta 1.45
Analysts Sell
Price Target $153.36

Latest News on CRL

Charles River Introduces Global Biotech Incubator Program

Dec 5, 2024, 8:00 AM EST - 4 months ago

Charles River Introduces Global Biotech Incubator Program


Charles River Laboratories Announces Third-Quarter 2024 Results

Nov 6, 2024, 7:00 AM EST - 6 months ago

Charles River Laboratories Announces Third-Quarter 2024 Results


Charles River to Perform Plasmid Manufacturing for AAVantgarde

Jul 8, 2024, 8:00 AM EDT - 10 months ago

Charles River to Perform Plasmid Manufacturing for AAVantgarde


A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL

Jun 14, 2024, 1:27 PM EDT - 11 months ago

A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL

LLY AMGN TMO